PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders. |
At the Annual Meeting of Stockholders of PhaseRx, Inc. (the
Company) held on May 25, 2017 (the Annual Meeting), the following
proposal was submitted to a vote of the Companys stockholders:
Election of seven directors to serve on the Companys board of
directors for a term of one year or until their successors are
elected and qualified, for which the following were nominees:
Robert W. Overell, Ph.D., Steven Gillis, Ph.D., Brian G. Atwood,
John A. Schmidt, Jr., M.D., Paul H. Johnson, Ph.D., Michelle
Griffin, and Peggy V. Phillips.
For more information about the foregoing proposal, see the
Companys definitive proxy statement for the Annual Meeting, filed
with the Securities and Exchange Commission on April 13, 2017,
the relevant portions of which are incorporated herein by
reference. Holders of the Companys common stock were entitled to
one vote per share. The number of votes cast for and against and
the number of abstentions and broker non-votes with respect to
each matter voted upon are set forth below.
Each of the following nominees for director received the number
of votes set forth opposite his or her name, constituting, in
each case, a plurality of the votes cast at the Annual Meeting
for the election of such director to serve for a term of one year
or until his or her successor is duly elected and qualified:
| Nominee | Votes For | Votes Withheld | Broker Non-Votes | |||
| Robert W. Overell, Ph.D. | 6,371,638 | 3,944 | ||||
| Steven Gillis, Ph.D. | 6,371,638 | 3,944 | ||||
| Brian G. Atwood | 6,371,638 | 3,944 | ||||
| John A. Schmidt, Jr., M.D. | 6,305,691 | 69,891 | ||||
| Paul H. Johnson, Ph.D. | 6,371,538 | 4,044 | ||||
| Michelle Griffin | 6,305,685 | 69,897 | ||||
| Peggy V. Phillips | 6,371,532 | 4,050 |
About PhaseRx, Inc. (NASDAQ:PZRX)
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle. PhaseRx, Inc. (NASDAQ:PZRX) Recent Trading Information
PhaseRx, Inc. (NASDAQ:PZRX) closed its last trading session down -0.03 at 1.05 with 22,927 shares trading hands.
